Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy

Atherosclerosis

Volumn 241, Issue 1, 2015, Pages 151-156

  Bugiardini, Raffaele ^a   Dorobantu, Maria ^b   Vasiljevic, Zorana ^c   Kedev, Sasko ^d   Knežević, Božidarka ^e   Miličić, Davor ^f   Calmac, Lucian ^b   Trninic, Dijana ^g   Daullxhiu, Irfan ^h   Cenko, Edina ^a   Ricci, Beatrice ^a   Puddu, Paolo Emilio ⁱ   Manfrini, Olivia ^a   Koller, Akos ^j,k   Badimon, Lina ^l  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Floreasca Emergency Hospital   (Romania)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^e UNIVERSITY OF MONTENEGRO   (Montenegro)

^f KBC Zagreb   (Croatia)

^g Clinical Center Banja Luka   (Bosnia and Herzegovina)

^h UNIVERSITY CLINICAL CENTER OF KOSOVO   (Serbia)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF PHYSICAL EDUCATION   (Hungary)

^k NEW YORK MEDICAL COLLEGE   (United States)

^l UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

Clopidogrel; Enoxaparin; No reperfusion therapy; Outcomes; ST segment elevation myocardial infarction; Unfractionated heparin

Indexed keywords

CLOPIDOGREL; ENOXAPARIN; HEMOGLOBIN; HEPARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; TICLOPIDINE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RISK REDUCTION; SIDE EFFECT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; EUROPE; HEALTH CARE SURVEY; HOSPITAL MORTALITY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; REGISTER; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; ENOXAPARIN; EUROPE; FEMALE; FIBRINOLYTIC AGENTS; HEALTH CARE SURVEYS; HEPARIN; HOSPITAL MORTALITY; HUMANS; INTRACRANIAL HEMORRHAGES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; REGISTRIES; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929306852     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.04.794     Document Type: Article

References (30)

1. O'Gara P.T., Kushner F.G., Ascheim D.D., Casey D.E., Chung M.K., de Lemos J.A., Ettinger S.M., Fang J.C., Fesmire F.M., Franklin B.A., Granger C.B., Krumholz H.M., Linderbaum J.A., Morrow D.A., Newby L.K., Ornato J.P., Ou N., Radford M.J., Tamis-Holland J.E., Tommaso C.L., Tracy C.M., Woo Y.J., Zhao D.X., Anderson J.L., Jacobs A.K., Halperin J.L., Albert N.M., Brindis R.G., Creager M.A., DeMets D., Guyton R.A., Hochman J.S., Kovacs R.J., Kushner F.G., Ohman E.M., Stevenson W.G., Yancy C.W. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 127:e362-e425. 10.1161/CIR.0b013e3182742cf6.
2. Steg P.G., James S.K., Atar D., Badano L.P., Blömstrom-Lundqvist C., Borger M.A., Di Mario C., Dickstein K., Ducrocq G., Fernandez-Aviles F., Gershlick A.H., Giannuzzi P., Halvorsen S., Huber K., Juni P., Kastrati A., Knuuti J., Lenzen M.J., Mahaffey K.W., Valgimigli M., van 't Hof A., Widimsky P., Zahger D. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012, 33:2569-2619. 10.1093/eurheartj/ehs215.
3. Jacobs A.K. Regionalized care for patients with ST-elevation myocardial infarction: it's closer than you think. Circulation 2006, 113:1159-1161. 10.1161/CIRCULATIONAHA.105.610345.
4. Gibson M.C. NRMI and current treatment patterns for ST-elevation myocardial infarction. Am. Heart J. 2004, 148:S29-S33. 10.1016/j.ahj.2004.09.012.
5. Sabatine M.S., Morrow D.A., Dalby A., Pfisterer M., Duris T., Lopez-Sendon J., Murphy S.A., Gao R., Antman E.M., Braunwald E. ExTRACT-TIMI 25 Investigators. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. J.Am. Coll. Cardiol. 2007, 49:2256-2563. 10.1016/j.jacc.2007.01.092.
6. Fassa A.A., Urban P., Radovanovic D., Duvoisin N., Gaspoz J.M., Stauffer J.C., Erne P. AMIS Plus Investigators. Trends in reperfusion therapy of ST segment elevation myocardial infarction in Switzerland: six year results from a nationwide registry. Heart. 2005, 91:882-888. 10.1136/hrt.2004.037689.
7. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., Thygesen K., Alpert J.S., White H.D., Jaffe A.S., Katus H.A., Apple F.S., Lindahl B., Morrow D.A., Chaitman B.A., Clemmensen P.M., Johanson P., Hod H., Underwood R., Bax J.J., Bonow R.O., Pinto F., Gibbons R.J., Fox K.A., Atar D., Newby L.K., Galvani M., Hamm C.W., Uretsky B.F., Steg P.G., Wijns W., Bassand J.P., Menasché P., Ravkilde J., Ohman E.M., Antman E.M., Wallentin L.C., Armstrong P.W., Simoons M.L., Januzzi J.L., Nieminen M.S., Gheorghiade M., Filippatos G., Luepker R.V., Fortmann S.P., Rosamond W.D., Levy D., Wood D., Smith S.C., Hu D., Lopez-Sendon J.L., Robertson R.M., Weaver D., Tendera M., Bove A.A., Parkhomenko A.N., Vasilieva E.J., Mendis S. ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur. Heart J. 2012, 33:2551-2567. Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. 10.1093/eurheartj/ehs184.
8. D'Agostino R.B., D'Agostino R.B. Estimating treatment effects using observational data. JAMA 2007, 297:314-316. 10.1001/jama.297.3.314.
9. Austin P.C. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom. J. 2009, 51:171-184. 10.1002/bimj.200810488.
10. Rogers W.J., Canto J.G., Lambrew C.T., Tiefenbrunn A.J., Kinkaid B., Shoultz D.A., Frederick P.D., Every N. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J.Am. Coll. Cardiol. 2000, 36:2056-2063. 10.1016/S0735-1097(00)00996-7.
11. Eagle K.A., Goodman S.G., Avezum A., Budaj A., Sullivan C.M., López-Sendón J. GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002, 359:373-377. 10.1016/S0140-6736(02)07595-5.
12. Tatu-Chitoiu G., Cinteza M., Dorobantu M., Udeanu M., Manfrini O., Pizzi C., Vintila M., Ionescu D.D., Craiu E., Burghina D., Bugiardini R. In-hospital case fatality of acute myocardial infarction in Romania. CMAJ 2009, 180:1207-1213. 10.1503/cmaj.081227.
13. Antman E.M., Morrow D.A., McCabe C.H., Murphy S.A., Ruda M., Sadowski Z., Budaj A., López-Sendón J.L., Guneri S., Jiang F., White H.D., Fox K.A., Braunwald E. ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N.Engl. J. Med. 2006, 354:1477-1488. 10.1056/NEJMoa060898.
14. Yusuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., Budaj A., Peters R.J., Bassand J.P., Wallentin L., Joyner C., Fox K.A. OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295:1519-1530. 10.1001/jama.295.13.joc60038.
15. Yusuf S., Mehta S.R., Xie C., Ahmed R.J., Xavier D., Pais P., Zhu J., Liu L. CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005, 293:427-435. 10.1001/jama.293.4.427.
16. Cohen M., Gensini G.F., Maritz F., Gurfinkel E.P., Huber K., Timerman A., Krzeminska-Pakula M., Danchin N., White H.D., Santopinto J., Bigonzi F., Hecquet C., Vittori L. TETAMI Investigators. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J.Am. Coll. Cardiol. 2003, 42:1348-1356. 10.1016/S0735-1097(03)01040-4.
17. Oldgren J., Wallentin L., Afzal R., Bassand J.P., Budaj A., Chrolavicius S., Fox K.A., Granger C.B., Mehta S.R., Pais P., Peters R.J., Xavier D., Zhu J., Yusuf S. OASIS-6 Investigators. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur. Heart J. 2008, 29:315-323. 10.1093/eurheartj/ehm578.
18. Cairns J.A., Theroux P., Lewis H.D., Ezekowitz M., Meade T.W. Antithrombotic agents in coronary artery disease. Chest 2001, 119(1 Suppl.l.):228S-252S. 10.1378/chest.119.1_suppl.228S.
19. Farrehi P.M., Ozaki C.K., Carmeliet P., Fay W.P. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 1998, 97:1002-1008. 10.1161/01.CIR.97.10.1002.
20. Montalescot G., Zeymer U., Silvain J., Boulanger B., Cohen M., Goldstein P., Ecollan P., Combes X., Huber K., Pollack C., Bénezet J.F., Stibbe O., Filippi E., Teiger E., Cayla G., Elhadad S., Adnet F., Chouihed T., Gallula S., Greffet A., Aout M., Collet J.P., Vicaut E. ATOLL Investigators. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011, 378:693-703. 10.1016/S0140-6736(11)60876-3.
21. Lincoff A.M., Steinhubl S.R., Manoukian S.V., Chew D., Pollack C.V., Feit F., Ware J.H., Bertrand M.E., Ohman E.M., Desmet W., Cox D.A., Mehran R., Stone G.W. Acute Catheterization and Urgent Intervention Triage strategY of Trial Investigators. Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin in Patients with non-st-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: An Analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial. JACC Cardiovasc. Interv. 2008, 1:639-648. 10.1016/j.jcin.2008.10.004.
22. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators Aclinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N.Engl. J. Med. 1997, 336:1621-1628. 10.1056/NEJM199706053362301.
23. Stone G.W., Cox D., Garcia E., Brodie B.R., Morice M.C., Griffin J., Mattos L., Lansky A.J., O'Neill W.W., Grines C.L. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001, 104:636-641. 10.1161/hc3101.093701.
24. De Feyter P.J., van Eenige M.J., van der Wall E.E., Bezemer P.D., van Engelen C.L., Funke-Kupper A.J., Kerkkamp H.J., Visser F.C., Roos J.P. Effects of spontaneous and streptokinase-induced recanalization on left ventricular function in in acute myocardial infarction. Circulation 1983, 67:1039-1044. 10.1161/01.CIR.67.5.1039.
25. Oler A., Whooley M.A., Oler J., Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996, 276:811-815. 10.1001/jama.1996.03540100055028.
26. COMMIT Collaborative Group Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet 2005, 366:1607-1621. 10.1016/S0140-6736(05)67660-X.
27. Wallentin L., Goldstein P., Armstrong P.W., Granger C.B., Adgey A.A., Arntz H.R., Bogaerts K., Danays T., Lindahl B., Mäkijärvi M., Verheugt F., Van de Werf F. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the pre-hospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003, 108:135-142. 10.1161/01.CIR.0000081659.72985.A8.
28. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001, 358:605-613. 10.1016/S0140-6736(01)05775-0.
29. Armstrong P.W., Chang W.C., Wallentin L., Goldstein P., Granger C.B., Bogaerts K., Danays T., Van de Werf F. ASSENT-3 and ASSENT-3 PLUS Investigators. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. CMAJ 2006, 174:1421-1426. 10.1503/cmaj.051410.
30. Gitt A.K., Bueno H., Danchin N., Fox K., Hochadel M., Kearney P., Maggioni A.P., Opolski G., Seabra-Gomes R., Weidinger F. The role of cardiac registries in evidence-based medicine. Eur. Heart J. 2010, 31:525-529. 10.1093/eurheartj/ehp596.